Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


immatics obtains important U.S. and European patents


Tuebingen, July 14, 2008 – immatics biotechnologies GmbH today announced that the company has obtained European patent protection for its technology platform XPRESIDENT™. In addition, the company has been granted important U.S. and European patents covering compounds contained in its lead product candidates IMA901 and IMA910.

“We are very pleased about the patents as they add to our growing IP portfolio in the field of peptide-based therapeutic vaccines and related compositions and technologies,” said Dr Niels Emmerich, Chief Operating Officer of immatics. “Most importantly, our XPRESIDENT™ core technology which is the engine for all our current and future products is now protected by an issued patent. Furthermore, the granting of patents for important peptides discovered through our XPRESIDENT™ technology platform confirms our IP strategy”

Recently, the EPO has granted patent protection of immatics’ XPRESIDENT™ drug discovery platform for the identification, selection and validation of novel tumor- associated peptides (TUMAPs). XPRESIDENT™ is a unique platform combining mass spectrometry, genomics, biochemistry, and immunology. Unlike other technologies, it is able to identify tumor-associated peptides (TUMAPs) directly from primary human tumor material, so that all TUMAPs are confirmed to be naturally processed and presented on real tumors.

XPRESIDENT™ also enables the detection of TUMAPs down to the femtomolar level – a sensitivity so far unrivaled. XPRESIDENT™ is able to identify several thousand TUMAPs per year and selects the most immunogenic antigens through a proprietary T cell validation platform. The platform can be applied to many different types of cancer.

Due to its sensitivity, XPRESIDENT™ is a very efficient discovery engine with an unprecedented and fast output of validated candidates for further clinical development.

The U.S. Patent and Trademark Office recently decided to grant a patent covering a TUMAP contained in immatics' drug candidates IMA901 and IMA910. Also, the

European Patent Office (EPO) issued a patent covering an additional peptide contained in IMA910. The patents cover composition of matter as well as medical use. IMA901 and IMA910, two peptide-based synthetic therapeutic vaccines for the treatment of renal cell cancer and colorectal cancer, respectively, are immatics’ clinical-stage drug candidates.

About IMA901 and IMA910
IMA901 and IMA910 are off-the-shelf cancer vaccines consisting of multiple fully synthetic tumor-associated peptides (TUMAPs), representing tumor antigens relevant for renal cell carcinoma and colorectal cancer, respectively. IMA901 is currently developed in a European multi-center Phase II clinical trial since 2007, while IMA910 entered into a European multi-center Phase I/II clinical trial in 2008. For both products, the TUMAPs were identified based on the analysis of primary tumor tissue and have been chosen due to their ability to activate cytotoxic T cells and T helper cells against cancer.

About immatics
immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Since its foundation in 2000, immatics has raised more than €54 million (US$ 73 million) in private equity in two financing rounds. The company has a headcount of more than 60 people and is based in Tuebingen and Munich, Germany.

For additional information please visit www.immatics.com or contact:

Dr Harpreet Singh
immatics biotechnologies GmbH
Phone: +49-7071-565125-10
E-mail: media@immatics.com


Publisher Contact Information:

immatics biotechnologies GmbH
+49-7071-565125-10
media@immatics.com

Company profile of immatics biotechnologies GmbH
Past press releases of immatics biotechnologies GmbH.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.